Who are the top three top 100 enterprises in China's pharmaceutical industry in 2018?

[industry trends of pharmaceutical network] on August 25, at the 2019 (36th) national pharmaceutical industry information annual meeting, the list of top 100 Chinese pharmaceutical enterprises in 2018 was released According to the statistics and analysis of China Pharmaceutical Industry Information Center, the top 100 enterprises in 2018 continued their consistent strong growth momentum, with the main business income scale reaching 839.55 billion yuan, with a growth rate of 11.8% Under the leading role of the top 100 enterprises, pharmaceutical industry enterprises have maintained strong revenue capacity and sufficient development momentum According to the list of top 100 enterprises in China's pharmaceutical industry in 2018, Jiangsu Yangzijiang Pharmaceutical Group ranked first, which is the group's five consecutive years of winning this award Following closely are Guangzhou Pharmaceutical Group Co., Ltd and China Pharmaceutical Group Co., Ltd According to the 2019 semi annual report released by Yangzijiang pharmaceutical, from January to June this year, the cumulative output value and sales of Yangzijiang pharmaceutical group increased by 11.22% and 12.68% respectively year on year At the same time, Yangzijiang pharmaceutical won the titles of 2018 top 100 innovative enterprises in Jiangsu Province and the first prize of science and technology award of Jiangsu Province On the 2019 China brand value evaluation list announced in May this year, Yangzijiang once again won the title of both brand strength and brand value in the medical health sector; five varieties of the group were shortlisted in the national scientific and technological competitiveness list of large varieties of traditional Chinese medicine In terms of R & D innovation, in 2018, Yangzijiang pharmaceutical won 10 production approvals for chemical drugs and traditional Chinese medicine, 2 innovative drugs entered clinical research, and 5 varieties achieved import substitution through the consistency evaluation of quality and efficacy of generic drugs Baiyunshan Pharmaceutical, a subsidiary of Guangzhou Pharmaceutical Group of Guangzhou Pharmaceutical Group, achieved an operating revenue of 33.341 billion yuan in the first half of 2019, a year-on-year increase of 124.67%; a total profit of 3.212 billion yuan, a year-on-year increase of 6.66%; and a net profit of 2.548 billion yuan, a year-on-year decrease of 2.73%, belonging to shareholders of listed companies Baiyunshan said in the report that there were two reasons for the year-on-year growth of performance On the one hand, it lies in the further development of its business in various sectors Among them, Wang Laoji health company, a wholly-owned subsidiary of Baiyunshan, implemented cost control and price maintenance measures and received government subsidies, resulting in a large increase in profits; on the other hand, due to the inclusion of pharmaceutical companies and Wang Laoji pharmaceutical industry in the scope of Baiyunshan merger, the main business income and profits increased year-on-year China Pharmaceutical Group is the first to break into the top three, ranking fourth last year It has 6 listed companies, including Sinopharm holding, Sinopharm, Sinopharm and Sinopharm Most of the performance of these subsidiaries is excellent, which gives strong impetus to the development of China Pharmaceutical Group Among them, Sinopharm's semi annual performance report in 2019 shows that in the first half of 2019, the company's operating revenue reached 21.012 billion yuan, an increase of 11.99% year-on-year; the net profit attributable to shareholders of listed companies was 755 million yuan, an increase of 18.66% year-on-year During the reporting period, the operating revenue of traditional Chinese medicine reached 6.937 billion yuan, a year-on-year increase of 27.02%; the equity holders of the company accounted for 859 million yuan, a year-on-year increase of 13% Sinopharm released the semi-annual performance report The data shows that in the first half of 2019, the company achieved an operating revenue of 21.012 billion yuan, an increase of 11.99% year-on-year; the net profit attributable to shareholders of the listed company was 755 million yuan, an increase of 18.66% year-on-year In the first half of 2019, Sinopharm achieved a revenue of 25.228 billion yuan, an increase of 21.42% year on year, and a net profit of 651 million yuan attributable to shareholders of the parent company, an increase of 1.42% year on year.